Rolvedon (Eflapegrastim-Xnst) Patent Expiration, LOE Window & CMS Spending

Rolvedon (Eflapegrastim-Xnst) by Spectrum Pharms: Biologic BLA (Purple Book Regime), 0 AB generics, $9.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSpectrum Pharms
FDA Application & PathwayB761148 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$9.5M
2024 Medicare Part D Spend$1.6M
2024 Medicaid Spend$7.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel